Key Takeaway: Artiva has raised $300 million to finance a Phase 3 trial for its AlloNK® cell therapy targeting refractory rheumatoid arthritis. The funding aims to advance the company's innovative approach to deep B-cell depletion, which is designed to be scalable and suitable for outpatient settings. This significant investment highlights Artiva's commitment to addressing autoimmune diseases.
Price reaction · baseline $7.67 (2026-05-26 close) · hit after-hours · 1 other ARTV headline(s) in the window, move may be shared
day 0 close
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Artiva secured $300 million in financing.
Funding will support a Phase 3 trial for AlloNK®.
Focus on developing an outpatient-ready treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+215%
120-day peak, hindsight
Typical move
13.1%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
Allogeneic NK Cells
Phase 2 · Refractory Rheumatoid Arthritis (RA)
Full Press Release Details
Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK® in autoimmune disease. The article discusses the company’s planned Phase 3 trial in refractory rheumatoid arthritis and its focus on developing an outpatient-ready, scalable approach to deep B-cell depletion.
Read the article here (subscription may be required).
The post SDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy appeared first on Artiva Biotherapeutics .
Frequently Asked Questions
What is the purpose of Artiva's Phase 3 trial?
The Phase 3 trial aims to evaluate AlloNK® for treating refractory rheumatoid arthritis.
How much funding did Artiva raise?
Artiva raised $300 million to support its clinical trial efforts.
What is AlloNK® designed to do?
AlloNK® focuses on deep B-cell depletion for autoimmune disease treatment.
Is the treatment outpatient-ready?
Yes, Artiva is developing an outpatient-ready approach for its therapy.